Jayadevappa R, Chhatre S, Malcowikz B, Parikh RB, Guzzo T, Wein AJ. Association between androgen deprivation therapy use and diagnosis of dementia in men with prostate cancer. JAMA Network Open 2019;2:e196562. [Ref.ID 103156]

Álvarez del Vayo M. Las asociaciones de pacientes recibieron casi seis millones de euros de la industria farmacéutica en 2016. CIVIO Medicamentalia 2018:19 de abril. [Ref.ID 102833]

Anónimo. Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone. European Medical Agency 2018:1. [Ref.ID 102552]

Anónimo. Flutamide: hépatites graves chez des femmes aussi. Prescrire 2017;37:427. [Ref.ID 102001]

Mackenzie IS, Morant SV, Wei L, Thompson AM, MacDonald TM. Spironolactone use and risk of incident cancers: a retrospective, matched cohort study. Br J Clin Pharmacol 2017;83:653-63. [Ref.ID 101935]

Wilt TJ, Jones KM, Barry MJ, Andriole GL, Culkin D, Wheeler T, Aronson WJ, Brawer MK. Follow-up of prostatectomy versus observation for early prostate cancer. N Engl J Med 2017;377:13 de julio. [Ref.ID 101914]

Anónimo. Flutamida: casos graves de hepatotoxicidad asociados al uso fuera de las condiciones autorizadas. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2017:27 de abril. [Ref.ID 101552]

Welk B, McArthur B, Ordon M, Anderson KK, Hayward J, Dixon S. Association of suicidality and depression with 5a-reductase inhibitors. JAMA Intern Med 2017;177:683-91. [Ref.ID 101479]

Nead KT, Gaskin G, Chester C, Swisher-McClure S, Leeper NJ, Shah NH. Association between androgen deprivation therapy and risk of dementia. JAMA Oncology 2016:13 de octubre. [Ref.ID 100814]

Anónimo. Pfizer announces planned acquisition of Medivation for $14 billion. DIA Daily 2016:1. [Ref.ID 100588]

O'Dowd A. Drug company is suspended from UK industry body after “deception on a grand scale”. BMJ 2016;353:i3574. [Ref.ID 100449]

Anónimo. Five facts about cancer survival in England. BMJ 2016;353:i3314. [Ref.ID 100437]

James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AWS, Parker CC, Russell JM, Attard G, de Bono J, Cross W, Jones RJ, Thalmann G, Amos C, Matheson D, Millman R, Alzouebi M, Beesley S, Birtle AJ, Brock S, Cathomas R, Chakraborti P, Chowdhury S, Cook A, Elliott T, Gale J, Gibbs S, Graham JD, Hetherington J, Hughes R, Laing R, McKinna F, McLaren DB, O'Sulllivan JM, Parikh O, Peedell C, Protheroe A, Robinson AJ, Srihari N, Srinivasan R, Staffurth J, Sundar S, Tolan S, Tsang D, Wagstaff J, Parmar MKB, STAMPEDE investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016;387:1163-77. [Ref.ID 100158]

Kowall B, Stang A, Rathmann W, Kostev K. No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK. Pharmacoepidemiol Drug Saf 2015;24:865-74. [Ref.ID 99853]

Anónimo. Enzalutamide et cancer de la prostate métastasé. Prescrire 2015;35:653-4. [Ref.ID 99711]

D'Amico AV, Chen M-H, Renshaw A, Loffredo M, Kantoff PW. Long-term follow-up of a randomized trial of radiation with or without androgen deprivation therapy for localized prostate cancer. JAMA 2015;314:1291-3. [Ref.ID 99525]

Hawkes N. NHS England drops 16 medicines from Cancer Drugs Fund. BMJ 2015;351:h4803. [Ref.ID 99469]

Hansen CM, Kragholm K, Pearson DA, Tyson C, Monk L, Byers B, Nelson D, Dupre ME, Fosbol L, Jollis JG, Strauss B, Anderson ML, McNally B, Granger CB. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA 2015;314:265-77. [Ref.ID 99360]

Sharfstein JM, Kesselheim AS. The safety of prescription drugs. JAMA 2015;314:233-4. [Ref.ID 99359]

O'Dowd A. Experts condemn "flawed" NICE process over its rejection of prostate cancer drug. BMJ 2014;349:g5224. [Ref.ID 98205]